Inflammatory B cells correlate with failure to checkpoint blockade in melanoma patients

The understanding of the role of B cells in patients with solid tumors remains insufficient. We found that circulating B cells produced TNF alpha and/or IL-6, associated with unresponsiveness and poor overall survival of melanoma patients treated with anti-CTLA4 antibody. Transcriptome analysis of B cells from melanoma metastases showed enriched expression of inflammatory response genes. Publicly available single B cell data from the tumor microenvironment revealed a negative correlation between TNF alpha expression and response to immune checkpoint blockade. These findings suggest that B cells contribute to tumor growth via the production of inflammatory cytokines. Possibly, these B cells are different from tertiary lymphoid structure-associated B cells, which have been described to correlate with favorable clinical outcome of cancer patients. Further studies are required to identify and characterize B cell subsets and their functions promoting or counteracting tumor growth, with the aim to identify biomarkers and novel treatment targets.

Automated summary

The role of B cells in solid tumor patients is insufficiently understood. Research suggests that B cells may promote tumor growth by producing inflammatory cytokines, affecting treatment response and overall survival. Different subsets of B cells may have varying impacts on tumor development, necessitating further study for identification and characterization.